Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
9.24
-0.74 (-7.41%)
Jun 3, 2026, 12:17 PM EDT - Market open
Fennec Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Fennec Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $15.57. The average 1-year stock price forecast is 68.51% higher than the current stock price, while the lowest is $13 (+40.69%) and the highest is $18 (+94.81%).
Price Target: $15.57 (+68.51%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Fennec Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Buy | 1 | 2 | 1 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Buy Maintains $15 | Buy | Maintains | $15 | +62.34% | May 22, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $13 → $16 | Buy | Reiterates | $13 → $16 | +73.16% | May 22, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $18 | Buy | Reiterates | $18 | +94.81% | May 15, 2026 |
Unknown Analyst Wedbush No rating | Wedbush | Buy Maintains $13 | Buy | Maintains | $13 | +40.69% | May 15, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Apr 22, 2026 |
Financial Forecast
Revenue This Year
72.02M
from 44.64M
Increased by 61.32%
Revenue Next Year
106.60M
from 72.02M
Increased by 48.02%
EPS This Year
0.26
from -0.34
EPS Next Year
0.94
from 0.26
Increased by 256.73%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 81.9M | 134.4M | ||||||
| Avg | 72.0M | 106.6M | ||||||
| Low | 66.2M | 83.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 83.4% | 86.6% | ||||||
| Avg | 61.3% | 48.0% | ||||||
| Low | 48.2% | 16.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.37 | 1.31 | ||||||
| Avg | 0.26 | 0.94 | ||||||
| Low | 0.18 | 0.54 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 395.6% | ||||||
| Avg | - | 256.7% | ||||||
| Low | - | 104.3% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.